SA
NAGE

Sycale Advisors’s Niagen Bioscience NAGE Stock Holding History

Sycale Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-714,404
Closed -$3.43M – 25
2020
Q4 		$3.43M Buy
714,404
+142,700
+25% +$696K 2.44% 13
2020
Q3 		$2.29M Buy
571,704
+211,958
+59% +$1.02M 1.97% 13
2020
Q2 		$1.65M Buy
359,746
+44,721
+14% +$200K 1.26% 13
2020
Q1 		$1.03M Hold
315,025
– – 0.76% 14
2019
Q4 		$1.36M Buy
+315,025
New +$1.12M 1.08% 13

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Sycale Advisors's NAGE Position: Q1 2021 in Review

Sycale Advisors sold out of Niagen Bioscience (NAGE) in Q1 2021, closing a stake of 714,404 shares — an estimated $3.43M sold.

Sycale Advisors first reported a position in NAGE in Q4 2019 and held it in 5 quarters. The position peaked at $3.43M in Q4 2020. 96 funds tracked by Wall St. Rank hold NAGE as of Q1 2021.

  • Sycale Advisors reported no remaining Niagen Bioscience position as of Q1 2021 after selling out during the quarter.
  • Sycale Advisors sold 714,404 Niagen Bioscience shares in Q1 2021, an estimated $3.43M.
  • Sycale Advisors first reported a position in Niagen Bioscience in Q4 2019 and held it in 5 quarters.
  • Sycale Advisors's Niagen Bioscience position peaked at $3.43M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2021.

Based on Sycale Advisors's 13F filing for Q1 2021, filed 3 May 2021.